Adverse prognostic markers included AGR2, IL6, MMP9, and TIMP1, whereas PAK3, Notch1, and B2M were linked to more prolonged survival or therapeutic responsiveness, underscoring the molecular heterogeneity of GBM. Here, MMP9 is linked to glioblastoma.